Editorial
The American College of Cardiology (ACC) is one of the most influential academic institutions worldwide and published the ACC expert consensus on nonstatins on April 1, 2016, which rapidly aroused wide public concern. [1] Since the publication of ACC/American Heart Association (ACC/AHA) guideline on cholesterol-lowering therapy in 2013, [2] an increasing number of clinical trials for nonstatins have been published. The milestone study IMPROVE-IT further validated the cholesterol theory and revitalized nonstatin cholesterol-lowering therapies using ezetimibe as a key representative. [3] Based on the cholesterol theory alone, the Food and Drug Administration (FDA) approved PCSK9 inhibitors without randomized clinical trials for cardiovascular endpoints. [4] This formed the basis for the ACC expert consensus on nonstatins, which was an excellent and necessary supplement for the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults.
Several highlights published in the ACC expert consensus on nonstatins are discussed below: 1. The ACC expert concept of a cholesterol-lowering target was reintroduced because most domestic and international experts believed it was more practical to set a cholesterol-lowering target that corresponded to cardiovascular risk stratification. After the 2013 ACC/AHA guideline on cholesterol-lowering therapy, a large discussion on repealing target value took place domestically. Experts in China did not adhere to ACC's point-of-view and insisted on reserving target values of low-density lipoprotein-cholesterol (LDL-C), thus reflecting a degree of academic independence The consensus recommended the use of ezetimibe across the four populations that would benefit from cholesterol-lowering therapy as a first option nonstatin lipid-lowering agent. Similarly, the European Medicine Agency (EMA) had approved ezetimibe for the new indication of cardiovascular event prevention in February of 2016. Both the ACC's recommendation and EMA's approval contradict the FDA Advisory Committee of Expert's point-of-view as it was recently considered controversial to expand the use of ezetimibe from the acute coronary syndromes (ACSs) population in IMPROVE-IT to all coronary heart disease (CHD) populations. In terms of this, the ACC's experts made quite a different recommendation with that by FDA Advisory Committee of Experts. Not long ago, FDA sent a response letter to the expansion in the indication of ezetimibe in the prevention of CHD and cardiovascular event according to the recommendations from the Advisory Committee of Experts. One of the focal points where the experts had a controversy at that time was whether the use of ezetimibe could be expanded from the ACS population in IMPROVE-IT to all the CHD populations. Thus it can be seen that the mainstream academia in US was closer to EMA in this point of view, EMA had approved the new indication of prevention of cardiovascular event for Ezetimibe in this February.
2. For the four major populations who would benefit from lipid-lowering therapy, the consensus emphasized the use of ezetimibe when the target was not achieved with high-intensity statins and fully recognized the cholesterol theory that lower LDL-C would be better. Promotion of the therapeutic strategy of high-intensity statins in a large area was not in accordance with the actual condition in China.
In patients where target LDL-C values were not achieved with both moderate or high-intensity statin therapy, and it was recognized that they would benefit from lipid-lowering therapy, the consensus emphasized the use of ezetimibe. This strategy would be suitable for patients in China as high-intensity statin therapy is not supported.
In reviewing the results of the IMPROVE-IT study, it first indicated that combined treatment with Ezetimibe and a statin significantly decreased LDL-C and cardiovascular risk compared to treatment with a statin alone. This study demonstrated cholesterol-lowering therapy, whether it be a statin or combined nonstatin therapy, can benefit patients. Furthermore, each reduction of 1 mM (38.7 mg/dL) plasma LDL-C can reduce the relative risk of cardiovascular disease (CVD) by approximately 20%, [5] consistent with the CTT meta-analysis in 2010. [6] Second, there is a correlation between CVD benefit and reduced LDL-C levels until at least 53 mg/dL. [7] If LDL-C exceeded 50 mg/dL, this benefit was considered independent from LDL-C. Third, by the 6-year follow-up, LDL-C levels were, on average, far <70 mg/dL and there no side effects or complications. Fourth, individuals aged <65 years (approximately half of the IMPROVE-IT study population) had a comparable benefit to younger patients showing that "it would never be too late to prevent CVD." Finally, IMPROVE-IT was designed to detect the benefit from two different LDL-C targets (70 mg/dL in the simvastatin group; 55 mg/dL in the simvastatin + ezetimibe group) rather than two fixed therapeutic strategies. Overall, the results from the IMPROVE-IT study support the idea of serum lipid target treatment for heart disease and atherosclerosis. [7] The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults recommends the use of high-intensity statins. However, even the highest doses of the most potent statins are unable to reduce LDL-C by more than 50% in many patients, i.e., patients with baseline LDL-C >140 mg/dL could not reach LDL-C <70 mg/dL. In addition, high doses of statins are not supported it in China, which has been clearly indicated in oversea guidelines and the Chinese consensus. The ISCAP study published in 2012 further confirmed that no additional clinical benefit could be produced with high-intensity statins in Chinese CHD patients who underwent PCI. [8] Atherosclerosis is progress develops progressively with age and is closely related to the LDL-C levels. Recently, Ge and Wang suggested that "Lower the LDL cholesterol to the level when you born." [9] It was proposed by Masana that based on experiences from the IMPROVE-IT study, hypercholesterolemia in high-risk patients could be better managed, and shift therapies focused on high-intensity statins to high-intensity cholesterol lowering [ Table 1 ]. Combined therapy (statins + ezetimibe) can achieve lower LDL target (only high-dose, high-intensity statin + ezetimibe could reduce LDL by more than 60%). [10] In addition, the use of ezetimibe could benefit patients that have difficulty tolerating high-intensity statin therapy.
To correctly understand the guideline and consensus, understanding the logic that they are based on is required. Ezetimibe combined with low-to moderate-intensity statins can reduce LDL-C by more than 50%, and had better efficacy, safety, and tolerability than the high-intensity statin therapy. Considering that high-intensity statin therapy is not suitable for the Chinese population, a nonstatin lipid-lowering approach could be adopted. Ezetimibe combined with a low-to moderate-intensity statin as a lipid-lowering regimen is more relevant to clinical practice than high doses of statins. 
